Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.60 |
| ▸ | AR | P10275 | 9/20 | 0.60 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | SHBG | P04278 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032618 | 1.00 | PGR (0.60) | PGRNR3C1ARSERPINA6ALDH1A1 | |
| SCHEMBL18306390 | 1.00 | PGR (0.60) | PGRNR3C1ARSERPINA6ALDH1A1 | |
| SCHEMBL19042720 | 1.00 | PGR (0.60) | PGRNR3C1ARSERPINA6ALDH1A1 | |
| SCHEMBL20048255 | 0.91 | PGR (0.62) | PGRNR3C1ARSERPINA6ALDH1A1 | |
| SCHEMBL23131152 | 0.91 | PGR (0.62) | PGRNR3C1ARSERPINA6ALDH1A1 | |
| SCHEMBL23131151 | 0.91 | PGR (0.55) | PGRNR3C1ARSERPINA6ALDH1A1 | |
| SCHEMBL21470226 | 0.91 | PGR (0.62) | PGRNR3C1ARSERPINA6ALDH1A1 | |
| SCHEMBL23131127 | 0.91 | PGR (0.53) | PGRNR3C1ARSERPINA6ALDH1A1 | |
| SCHEMBL23645233 | 0.90 | PGR (0.62) | PGRNR3C1ARSERPINA6ALDH1A1 | |
| SCHEMBL20048414 | 0.90 | PGR (0.62) | PGRNR3C1ARSERPINA6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087211-B2 | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties | RESEARCH TRIANGLE INSTITUTE (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170051008-A1 | ANDROSTANE AND PREGNANE STEROIDS WITH POTENT ALLOSTERIC GABA RECEPTOR CHLORIDE IONOPHORE MODULATING PROPERTIES | RESEARCH TRIANGLE INSTITUTE (US) | 2017-02-23 | — | — | US | disclosed |
| US-9518080-B2 | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties | RESEARCH TRIANGLE INSTITUTE (US) | 2016-12-13 | — | — | US | disclosed |
| EP-2155204-B1 | ANDROSTANE AND PREGNANE STEROIDS WITH POTENT ALLOSTERIC GABA RECEPTOR CHLORIDE IONOPHORE MODULATING PROPERTIES | RES TRIANGLE INST (US) | 2016-08-17 | — | — | EP | disclosed |
| US-8575375-B2 | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties | RESEARCH TRIANGLE INSTITUTE (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110092473-A1 | ANDROSTANE AND PREGNANE STEROIDS WITH POTENT ALLOSTERIC GABA RECEPTOR CHLORIDE IONOPHORE MODULATING PROPERTIES | RESEARCH TRIANGLE INSTITUTE (US) | 2011-04-21 | — | — | US | disclosed |
| EP-0404283-B1 | 11-Beta-aryl-4-estrene, method for its production and its use as a medicine | SCHERING AG (DE) | 1996-05-08 | — | — | EP | disclosed |
| EP-0404283-A2 | 11-Beta-aryl-4-estrene, method for its production and its use as a medicine | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170051008-A1 | ANDROSTANE AND PREGNANE STEROIDS WITH POTENT ALLOSTERIC GABA RECEPTOR CHLORIDE IONOPHORE MODULATING PROPERTIES | GABRA2, GABRA1, GABRA4 | PGR 50/4885NR3C1 17/4885AR 146/4885 |
| US-20110092473-A1 | ANDROSTANE AND PREGNANE STEROIDS WITH POTENT ALLOSTERIC GABA RECEPTOR CHLORIDE IONOPHORE MODULATING PROPERTIES | GABRA2, GABRA1, GABRA4 | PGR 50/4885NR3C1 17/4885AR 146/4885 |
| US-10087211-B2 | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties | GABRA2, GABRA1, GABRA4 | PGR 50/4885NR3C1 17/4885AR 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.